SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
Monopar Therapeutics Inc.
(Name of Issuer)
Common Stock, $0.001 par value
(Title of Class of Securities)
61023L207
(CUSIP Number)
October 23, 2024
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
| ¨ | Rule 13d-1(b) |
| x | Rule 13d-1(c) |
| ¨ | Rule 13d-1(d) |
*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
Schedule 13G
| CUSIP No. 61023L207 |
| |
| | 1. | Name of Reporting Person
AstraZeneca PLC |
| |
| | 2. | Check the Appropriate Box if a Member of a Group (See Instructions) |
| | | (a) | ¨ |
| | | (b) | x (Joint filers) |
| |
| | 3. | SEC Use Only |
| |
| | 4. | Citizenship or Place of Organization
United Kingdom |
| | | |
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With | 5. | Sole Voting Power
387,329 shares1 |
| |
| 6. | Shared Voting Power
0 shares |
| |
| 7. | Sole Dispositive Power
387,329 shares2 |
| |
| 8. | Shared Dispositive Power
0 shares |
| |
| | 9. | Aggregate Amount Beneficially Owned by Each Reporting Person
387,329 shares3 |
| |
| | 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ |
| |
| | 11. | Percent of Class Represented by Amount in Row (9)
9.9%4 |
| |
| | 12. | Type of Reporting Person (See Instructions)
CO |
| | | | | | |
1 Represents shares directly held by Alexion Pharmaceuticals, Inc., a wholly-owned subsidiary of AstraZeneca PLC. AstraZeneca PLC and Alexion Pharmaceuticals, Inc. (collectively, the “Reporting Persons”) may each be deemed to have sole voting and dispositive power over the shares.
2 See footnote 1.
3 See footnote 1.
4 The percentage ownership was calculated based on a total of 3,912,408 shares of common stock, $0.001 par value (“Common Stock”), of Monopar Therapeutics Inc. (the “Issuer”) outstanding, which includes (i) 3,525,079 shares of Common Stock outstanding as of October 23, 2024 (without giving effect to the issuance of shares of Common Stock being reported hereunder), according to information received from the Issuer on October 23, 2024, plus (ii) the 387,329 shares of Common Stock issued to the Reporting Persons on October 23, 2024.
Schedule 13G
| CUSIP No. 61023L207 |
| |
| | 1. | Name of Reporting Person
Alexion Pharmaceuticals, Inc. |
| |
| | 2. | Check the Appropriate Box if a Member of a Group (See Instructions) |
| | | (a) | ¨ |
| | | (b) | x (Joint filers) |
| |
| | 3. | SEC Use Only |
| |
| | 4. | Citizenship or Place of Organization
Delaware |
| | | |
Number of
Shares
Beneficially
Owned by
Each
Reporting
Person With | 5. | Sole Voting Power
387,329 shares5 |
| |
| 6. | Shared Voting Power
0 shares |
| |
| 7. | Sole Dispositive Power
387,329 shares6 |
| |
| 8. | Shared Dispositive Power
0 shares |
| |
| | 9. | Aggregate Amount Beneficially Owned by Each Reporting Person
387,329 shares7 |
| |
| | 10. | Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions) ¨ |
| |
| | 11. | Percent of Class Represented by Amount in Row (9)
9.9%8 |
| |
| | 12. | Type of Reporting Person (See Instructions)
CO |
| | | | | | |
5 See footnote 1.
6 See footnote 1.
7 See footnote 1.
8 See footnote 4.
CUSIP No. 61023L207
| Item 1. |
| | (a) | Name of Issuer
Monopar Therapeutics Inc. |
| | (b) | Address of Issuer’s Principal Executive Offices
1000 Skokie Blvd., Suite 350, Wilmette, IL, 60091 |
| |
| Item 2. |
| | (a) | Name of Person Filing
See response to 2(c) |
| | (b) | Address of Principal Business Office or, if none, Residence
See response to 2(c) |
| | (c) | Citizenship
This statement is filed on behalf of: AstraZeneca PLC 1 Francis Crick Avenue Cambridge Biomedical Campus Cambridge CB2 0AA United Kingdom Citizenship: United Kingdom Alexion Pharmaceuticals, Inc. 121 Seaport Blvd. Boston, Massachusetts 02210 United States Citizenship: United States |
| | (d) | Title of Class of Securities
Common Stock, $0.001 par value |
| | (e) | CUSIP Number
61023L207 |
| |
| Item 3. | If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: |
| | (a) | ¨ | Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o); |
| | (b) | ¨ | Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c); |
| | (c) | ¨ | Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c); |
| | (d) | ¨ | Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8); |
| | (e) | ¨ | An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); |
| | (f) | ¨ | An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); |
| | (g) | ¨ | A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G); |
| | (h) | ¨ | A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); |
| | (i) | ¨ | A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); |
| | (j) | ¨ | A non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J); |
| | (k) | ¨ | Group, in accordance with § 240.13d–1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d–1(b)(1)(ii)(J), please specify the type of institution:____________________________ |
| Item 4. | Ownership |
| Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. |
| | (a) | Amount beneficially owned: 387,329 shares |
| | (b) | Percent of class: 9.9%. The percentage stated herein is based on a total of 3,912,408 shares of the Issuer’s Common Stock outstanding, which includes (i) 3,525,079 shares of Common Stock outstanding as of October 23, 2024 (without giving effect to the issuance of shares of Common Stock being reported hereunder), according to information received from the Issuer on October 23, 2024, plus (ii) the 387,329 shares of Common Stock issued to the Reporting Persons on October 23, 2024. |
| | (c) | Number of shares as to which the person has: |
| | | (i) | Sole power to vote or to direct the vote: AstraZeneca PLC: 387,329 shares Alexion Pharmaceuticals, Inc.: 387,329 shares |
| | | (ii) | Shared power to vote or to direct the vote: AstraZeneca PLC: 0 shares Alexion Pharmaceuticals, Inc.: 0 shares |
| | | (iii) | Sole power to dispose or to direct the disposition of: AstraZeneca PLC: 387,329 shares Alexion Pharmaceuticals, Inc.: 387,329 shares |
| | | (iv) | Shared power to dispose or to direct the disposition of: AstraZeneca PLC: 0 shares Alexion Pharmaceuticals, Inc.: 0 shares |
Alexion Pharmaceuticals, Inc., a wholly owned subsidiary of AstraZeneca PLC, is the direct record holder of all 387,329 shares reported herein. Each of Alexion Pharmaceuticals, Inc. and AstraZeneca PLC may be deemed to have sole voting and dispositive power with respect to such shares. |
| Item 5. | Ownership of Five Percent or Less of a Class |
| If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. ¨ |
| |
| Item 6. | Ownership of More than Five Percent on Behalf of Another Person |
| Not applicable. |
| Item 7. | Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person |
| Not applicable. |
| |
| Item 8. | Identification and Classification of Members of the Group |
| Not applicable. |
| |
| Item 9. | Notice of Dissolution of Group |
| Not applicable. |
| |
| Item 10. | Certifications |
| By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11. |
Signatures
After reasonable inquiry and to the best of the knowledge and belief of each of the undersigned, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.
October 28, 2024
| | AstraZeneca PLC /s/ Adrian Kemp |
| | Signature |
| | |
| |
Adrian Kemp, Company Secretary |
| | Name/Title |
| | Alexion Pharmaceuticals, Inc. /s/ Todd Spalding |
| | Signature |
| | |
| |
Todd Spalding, Secretary |
| | Name/Title |
Attention: Intentional misstatements or omissions of fact constitute federal criminal violations (see 18 U.S.C. 1001).
Exhibit Index
